The Bottom Line on Atossa Genetics Inc. (ATOS), Humana Inc. (HUM)

Atossa Genetics Inc. (NASDAQ:ATOS) shares were trading higher by 1.29 percent ($0) at $0.36 a piece in Tuesday’s session. It had closed the previous session at $0.36. . Shares of ATOS have downtrended -13.69% in the past three months. Atossa Genetics Inc. (ATOS) has a market cap of $5.13 million and over the last 12 months, Atossa Genetics Inc. (NASDAQ:ATOS) has gone weaker by -80.51%. During the last 52 weeks, the (NASDAQ:ATOS) price has been as high as $2.6 and as low as $0.31. Atossa Genetics Inc. earnings have risen with an annualized rate of 17.5% over the last 5 years.
Is Humana Inc. (NYSE:HUM) Cheap From Peers?

Humana Inc. (HUM) pulled off a 1.26 percent gain and now trades for $236.42. HUM comes in with a P/S ratio of 0.64 that’s below 1, potentially implying that it could be cheap relative to the overall sector (5.28) and its peers (0.88). Also, it has an estimated price-earnings (P/E) multiple of 19.47 and a trailing 12-month price-earnings (P/E) multiple of 18.61. During the last 52 weeks, the price has been as high as $264.56 and as low as $186.25. Humana Inc. (NYSE:HUM) earnings have risen with a quarterly rate of 8.1% over the last 5 years. Shares of HUM have sank -6.18% in the past three monthswhile the S&P 500 has dropped -11.94% in that time.
Humana Inc. (Price Objective: $258.28)

Humana Inc. (NYSE:HUM) has a market cap of $34.13 billion and over the last 12 months, HUM has risen by 18.22%. The average 1-year price target for (HUM) reveals an average price target of $258.28 per share. That’s a potential 9.25 gain from where (NYSE:HUM) has been trading recently. There are brokerage firms with lower targets than the average, including one setting a price target of $151. And then on the other side of the spectrum one analyst entrenched in the bullish camp has a target as high as $290.
Analyst Thoughts About Humana Inc. (NYSE:HUM)

The consensus recommendation — averaging the work of 19 analysts — of 2 for Humana Inc. (HUM) points to moderate case. Of the analysts surveyed by Reuters that track Humana Inc. 7 of them rate its stock a hold. The other 12 are split, though not evenly, between analysts who think you should buy its stock versus those who think you should sell it. A 12 analysts rate it as either a buy or a strong buy, while 0 believe that investors should either steer clear of (NYSE:HUM) or, if they already own its stock, sell it.